Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice
- 18 December 2017
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (2) , 359-373
Abstract
Background and Purpose: Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for the NmU‐mediated anti‐obesity effects, the receptor agonist with the most appropriate profiles for treating obesity and diabetes in terms of efficacy and safety is as yet unknown. Thus, we developed and evaluated novel NMU1/2 receptor‐selective agonists.Experimental Approach: Efficacy and safety were assessed in mice with diet‐induced obesity (DIO) and those with leptin‐deficient diabetes (ob/ob) through repeated peripheral administration of selective agonists to NMU1 (NMU‐6102) and NMU2 (NMU‐2084), along with non‐selective NMU1/2 agonists (NMU‐0002 and NMU‐6014). We also performed immunohistochemistry for c‐Fos protein expression in the brain to probe their mechanisms of action.Key Results: Although both non‐selective NMU1/2 agonists and the NMU2‐selective agonist had high efficacy compared with the NMU1‐selective agonist, only the NMU2‐selective agonist led to relatively low adverse effects, such as diarrhoea, in DIO mice. However, the non‐selective NMU1/2 agonist and the NMU1‐selective agonist, but not the NMU2‐selective agonist, were effective in diabetic ob/ob mice. Mechanistically, NMU2‐selective agonists preferentially activate pro‐opiomelanocortin neurons in the hypothalamic arcuate nucleus but not in the paraventricular nucleus.Conclusions and Implications: These results suggest that an NMU2 receptor‐selective agonist may be a well‐balanced drug for the treatment of obesity and that an NMU1 receptor‐selective agonist may also be beneficial for treating obesity and diabetes once its side effects are minimized.Keywords
This publication has 58 references indexed in Scilit:
- Regulation of motivation for food by neuromedin U in the paraventricular nucleus and the dorsal raphe nucleusInternational Journal of Obesity, 2016
- Experimental design and analysis and their reporting: new guidance for publication in BJPBritish Journal of Pharmacology, 2015
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Neuromedin U is necessary for normal gastrointestinal motility and is regulated by serotoninAnnals of the New York Academy of Sciences, 2010
- Neuroendocrine Control of the Gut During Stress: Corticotropin-Releasing Factor Signaling Pathways in the SpotlightAnnual Review of Physiology, 2009
- Association between Neuromedin U Gene Variants and Overweight and ObesityThe Journal of Clinical Endocrinology & Metabolism, 2006
- A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J miceDiabetologia, 2005
- Chronic administration of NMU into the paraventricular nucleus stimulates the HPA axis but does not influence food intake or body weightBiochemical and Biophysical Research Communications, 2004
- Neuromedin U and Neuromedin U receptor‐2 expression in the mouse and rat hypothalamus: effects of nutritional statusJournal of Neurochemistry, 2003
- Evaluation of Neuromedin U Actions in Energy Homeostasis and Pituitary FunctionEndocrinology, 2002